{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:50:48Z","timestamp":1776819048650,"version":"3.51.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372736"],"award-info":[{"award-number":["82372736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-09801-w","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:05:22Z","timestamp":1773032722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual targeting of topoisomerase I and DNA G-quadruplexes enhances senescence and chemosensitivity in colorectal cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Yameng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enwei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-0573","authenticated-orcid":false,"given":"Ming-Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-798X","authenticated-orcid":false,"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-6735","authenticated-orcid":false,"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"9801_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","volume":"29","author":"J Roelands","year":"2023","unstructured":"Roelands, J. et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat. Med. 29, 1273\u20131286 (2023).","journal-title":"Nat. Med."},{"key":"9801_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(18)32252-9","volume":"392","author":"T Lancet","year":"2018","unstructured":"Lancet, T. GLOBOCAN 2018: counting the toll of cancer. Lancet 392, 985 (2018).","journal-title":"Lancet"},{"key":"9801_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jama.2015.9379","volume":"314","author":"JR Berian","year":"2015","unstructured":"Berian, J. R., Benson, A. B. III. & Nelson, H. Young age and aggressive treatment in colon cancer. J. Am. Med. Assoc. 314, 613\u2013614 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"9801_CR4","doi-asserted-by":"publisher","unstructured":"Willyard, C. The colon cancer conundrum. Nature https:\/\/doi.org\/10.1038\/d41586-021-03405-6 (2021).","DOI":"10.1038\/d41586-021-03405-6"},{"key":"9801_CR5","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/0008-5472.CAN-18-3024","volume":"79","author":"C Liu","year":"2019","unstructured":"Liu, C., Banister, C. E. & Buckhaults, P. J. Spindle assembly checkpoint inhibition can resensitize p53-null stem cells to cancer chemotherapy. Cancer Res. 79, 2392\u20132403 (2019).","journal-title":"Cancer Res."},{"key":"9801_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2014-0159","volume":"19","author":"Y Hamamoto","year":"2014","unstructured":"Hamamoto, Y. et al. A phase I\/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer. Oncologist 19, 1131\u20131132 (2014).","journal-title":"Oncologist"},{"key":"9801_CR7","doi-asserted-by":"publisher","first-page":"e2011036","DOI":"10.1001\/jamanetworkopen.2020.11036","volume":"3","author":"W Lu","year":"2020","unstructured":"Lu, W. et al. Effect of reduced-dose capecitabine plus cetuximab as maintenance therapy for RAS wild-type metastatic colorectal cancer: a phase 2 clinical trial. JAMA Netw. open 3, e2011036 (2020).","journal-title":"JAMA Netw. open"},{"key":"9801_CR8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/cas.14312","volume":"111","author":"L Luput","year":"2020","unstructured":"Luput, L. et al. Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci. 111, 1344\u20131356 (2020).","journal-title":"Cancer Sci."},{"key":"9801_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01517-9","volume":"21","author":"Z Shi","year":"2022","unstructured":"Shi, Z. et al. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol. Cancer 21, 37 (2022).","journal-title":"Mol. Cancer"},{"key":"9801_CR10","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.7150\/thno.30678","volume":"9","author":"SH Park","year":"2019","unstructured":"Park, S. H. et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics 9, 2235\u20132251 (2019).","journal-title":"Theranostics"},{"key":"9801_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-64","volume":"10","author":"C Gongora","year":"2011","unstructured":"Gongora, C. et al. New Topoisomerase I mutations are associated with resistance to camptothecin. Mol. Cancer 10, 64 (2011).","journal-title":"Mol. Cancer"},{"key":"9801_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2625","volume":"12","author":"F Coussy","year":"2020","unstructured":"Coussy, F. et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci. Transl. Med. 12, eaax2625 (2020).","journal-title":"Sci. Transl. Med."},{"key":"9801_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/cancers11101416","volume":"11","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Tyrosyl-DNA phosphodiesterase 1 and topoisomerase I activities as predictive indicators for Glioblastoma susceptibility to genotoxic agents. Cancers 11, 1416 (2019).","journal-title":"Cancers"},{"key":"9801_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc3646","volume":"6","author":"L Jingjing","year":"2020","unstructured":"Jingjing, L. et al. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci. Adv. 6, eabc3646 (2020).","journal-title":"Sci. Adv."},{"key":"9801_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1078-0432.CCR-12-1201","volume":"19","author":"G Jameson","year":"2013","unstructured":"Jameson, G. et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 19, 268\u2013278 (2013).","journal-title":"Clin. Cancer Res."},{"key":"9801_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2019.04.009","volume":"514","author":"B Lee","year":"2019","unstructured":"Lee, B. et al. A novel mechanism of irinotecan targeting MDM2 and Bcl-xL. Biochem. Biophys. Res. Commun. 514, 518\u2013523 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"9801_CR17","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti, F. et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics(Article). J. Clin. Oncol. 27, 2604\u20132614 (2009).","journal-title":"J. Clin. Oncol."},{"key":"9801_CR18","doi-asserted-by":"publisher","first-page":"118499","DOI":"10.1016\/j.ijpharm.2019.118499","volume":"568","author":"J Si","year":"2019","unstructured":"Si, J., Zhao, X., Gao, S., Huang, D. & Sui, M. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin. Int. J. Pharm. 568, 118499 (2019).","journal-title":"Int. J. Pharm."},{"key":"9801_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/bc0155420","volume":"12","author":"PD Senter","year":"2001","unstructured":"Senter, P. D., Beam, K. S., Mixan, B. & Wahl, A. F. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjugate Chem. 12, 1074\u20131080 (2001).","journal-title":"Bioconjugate Chem."},{"key":"9801_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1248\/bpb.17.662","volume":"17","author":"T Satoh","year":"1994","unstructured":"Satoh, T. et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 17, 662\u2013664 (1994).","journal-title":"Biol. Pharm. Bull."},{"key":"9801_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9666-7_1","volume":"2035","author":"D Yang","year":"2019","unstructured":"Yang, D. G-Quadruplex DNA and RNA. Methods Mol. Biol. 2035, 1\u201324 (2019).","journal-title":"Methods Mol. Biol."},{"key":"9801_CR22","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/nar\/gki553","volume":"33","author":"AK Todd","year":"2005","unstructured":"Todd, A. K., Johnston, M. & Neidle, S. Highly prevalent putative quadruplex sequence motifs in human DNA. Nucleic Acids Res. 33, 2901\u20132907 (2005).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/genes13091665","volume":"13","author":"J Rauchhaus","year":"2022","unstructured":"Rauchhaus, J., Robinson, J. & Monti, L. G-quadruplexes mark sites of methylation instability associated with ageing and cancer. Genes 13, 1665 (2022).","journal-title":"Genes"},{"key":"9801_CR24","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1007\/s00018-021-03921-8","volume":"78","author":"F Teng","year":"2021","unstructured":"Teng, F. et al. G-quadruplex DNA: a novel target for drug design. Cell. Mol. Life Sci. 78, 6557\u20136583 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"9801_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/nar\/gkae835","volume":"53","author":"Q-F Yang","year":"2025","unstructured":"Yang, Q.-F. et al. G4LDB 3.0: a database for discovering and studying G-quadruplex and i-motif ligands. Nucleic Acids Res. 53, 91\u201398 (2025).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.chempr.2018.02.014","volume":"4","author":"T Tian","year":"2018","unstructured":"Tian, T., Chen, Y., Wang, S. & Zhou, X. G-Quadruplex: a regulator of gene expression and its chemical targeting. Chem 4, 1314\u20131344 (2018).","journal-title":"Chem"},{"key":"9801_CR27","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1021\/acs.jmedchem.3c02127","volume":"67","author":"M Andreasson","year":"2024","unstructured":"Andreasson, M. et al. Exploring the dispersion and electrostatic components in arene\u2013arene interactions between ligands and G4 DNA to develop G4-ligands. J. Med. Chem. 67, 2202\u20132219 (2024).","journal-title":"J. Med. Chem."},{"key":"9801_CR28","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.7150\/thno.19506","volume":"7","author":"T Liu","year":"2017","unstructured":"Liu, T. et al. RBFOX3 promotes tumor growth and progression via hTERT signaling and predicts a poor prognosis in hepatocellular carcinoma. Theranostics 7, 3138\u20133154 (2017).","journal-title":"Theranostics"},{"key":"9801_CR29","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1126\/science.1138596","volume":"315","author":"SB Cohen","year":"2007","unstructured":"Cohen, S. B. et al. Protein composition of catalytically active human telomerase from immortal cells. Sci 315, 1850\u20131853 (2007).","journal-title":"Sci"},{"key":"9801_CR30","doi-asserted-by":"publisher","first-page":"12331","DOI":"10.1021\/ja101252n","volume":"132","author":"KW Lim","year":"2010","unstructured":"Lim, K. W. et al. Coexistence of two distinct G-quadruplex conformations in the hTERT promoter. J. Am. Chem. Soc. 132, 12331\u201312342 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"9801_CR31","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1093\/nar\/gkaa107","volume":"48","author":"RC Monsen","year":"2020","unstructured":"Monsen, R. C. et al. The hTERT core promoter forms three parallel G-quadruplexes. Nucleic Acids Res. 48, 5720\u20135734 (2020).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR32","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1021\/acs.jmedchem.4c01255","volume":"67","author":"L Wei","year":"2024","unstructured":"Wei, L. et al. Targeting hTERT promoter G-quadruplex DNA structures with small-molecule ligand to downregulate hTERT expression for triple-negative breast cancer therapy. J. Med. Chem. 67, 13363\u201313382 (2024).","journal-title":"J. Med. Chem."},{"key":"9801_CR33","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/ja973792e","volume":"120","author":"RT Wheelhouse","year":"1998","unstructured":"Wheelhouse, R. T., Sun, D., Han, H., Han, F. X. & Hurley, L. H. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J. Am. Chem. Soc. 120, 3261\u20133262 (1998).","journal-title":"J. Am. Chem. Soc."},{"key":"9801_CR34","first-page":"337","volume":"24","author":"M Zhou","year":"2014","unstructured":"Zhou, M., He, X., Shi, W. & Zhong, B. Synthesis and preliminary evaluation of novel 10-substituted 7-ethyl-10-hydroxy camptothecin(SN38) prodrugs. Chin. J. Med. Chem. 24, 337\u2013344 (2014).","journal-title":"Chin. J. Med. Chem."},{"key":"9801_CR35","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cmdc.202000753","volume":"16","author":"X-Y Yang","year":"2021","unstructured":"Yang, X.-Y. et al. Synthesis and biological evaluation of 10-substituted camptothecin derivatives with improved water solubility and activity. ChemMed Chem. 16, 1000\u20131010 (2021).","journal-title":"ChemMed Chem."},{"key":"9801_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"491","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nat 491, 603\u2013607 (2012).","journal-title":"Nat"},{"key":"9801_CR37","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1021\/jm049146p","volume":"48","author":"BL Staker","year":"2005","unstructured":"Staker, B. L. et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48, 2336\u20132345 (2005).","journal-title":"J. Med. Chem."},{"key":"9801_CR38","first-page":"1","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang, S., Tischer, T. & Barford, D. Cyclin A2 degradation during the spindle assembly checkpoint requires multiple binding modes to the APC\/C. Nat. Commun. 10, 1\u201316 (2019).","journal-title":"Nat. Commun."},{"key":"9801_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0270165","volume":"17","author":"RC Monsen","year":"2022","unstructured":"Monsen, R. C., Maguire, J. M., DeLeeuw, L. W., Chaires, J. B. & Trent, J. O. Drug discovery of small molecules targeting the higher-order hTERT promoter G-quadruplex. PLoS One 17, 1\u201325 (2022).","journal-title":"PLoS One"},{"key":"9801_CR40","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1093\/nar\/gkab330","volume":"49","author":"J Dickerhoff","year":"2021","unstructured":"Dickerhoff, J., Dai, J. & Yang, D. Structural recognition of the MYC promoter G-quadruplex by a quinoline derivative: insights into molecular targeting of parallel G-quadruplexes. Nucleic Acids Res. 49, 5905\u20135915 (2021).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR41","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1093\/nar\/gkn120","volume":"36","author":"S Cogoi","year":"2008","unstructured":"Cogoi, S., Paramasivam, M. & Spolaore, B. Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins. Nucleic Acids Res. 36, 3765\u20133780 (2008).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR42","doi-asserted-by":"publisher","first-page":"13399","DOI":"10.1021\/ja904007p","volume":"131","author":"STD Hsu","year":"2009","unstructured":"Hsu, S. T. D. et al. A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics. J. Am. Chem. Soc. 131, 13399 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"9801_CR43","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1093\/nar\/gkaa262","volume":"48","author":"A Ou","year":"2020","unstructured":"Ou, A. et al. High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A \u03c0-stacking interactions for small-molecule recognition. Nucleic Acids Res. 48, 5766\u20135776 (2020).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR44","doi-asserted-by":"publisher","first-page":"11059","DOI":"10.1021\/jacs.9b02679","volume":"141","author":"K-B Wang","year":"2019","unstructured":"Wang, K.-B. et al. Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the MYC promoter G-quadruplex and downregulate MYC. J. Am. Chem. Soc. 141, 11059\u201311070 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"9801_CR45","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1021\/ja055636a","volume":"128","author":"J Dai","year":"2006","unstructured":"Dai, J. et al. An intramolecular G-quadruplex structure with mixed parallel\/antiparallel G-strands formed in the human BCL-2 promoter region in solution. J. Am. Chem. Soc. 128, 1096\u20131098 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"9801_CR46","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/nar\/gky1179","volume":"47","author":"A Sengar","year":"2019","unstructured":"Sengar, A. et al. Structure of a (3+1) hybrid G-quadruplex in the PARP1 promoter. Nucleic Acids Res. 47, 1564\u20131572 (2019).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR47","doi-asserted-by":"publisher","first-page":"10584","DOI":"10.1093\/nar\/gkt784","volume":"41","author":"P Agrawal","year":"2013","unstructured":"Agrawal, P., Hatzakis, E., Guo, K., Carver, M. & Yang, D. Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes. Nucleic Acids Res. 41, 10584\u201310592 (2013).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR48","first-page":"11931","volume":"47","author":"W Liu","year":"2019","unstructured":"Liu, W. et al. Structures of 1:1 and 2:1 complexes of BMVC and MYC promoter G-quadruplex reveal a mechanism of ligand conformation adjustment for G4-recognition. Nucleic Acids Res. 47, 11931\u201311942 (2019).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR49","doi-asserted-by":"publisher","first-page":"awac001","DOI":"10.1093\/brain\/awac001","volume":"145","author":"F Cheng","year":"2022","unstructured":"Cheng, F. et al. DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family. Brain 145, awac001 (2022).","journal-title":"Brain"},{"key":"9801_CR50","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/nar\/28.3.669","volume":"28","author":"S Kyo","year":"2000","unstructured":"Kyo, S. et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28, 669\u2013677 (2000).","journal-title":"Nucleic Acids Res."},{"key":"9801_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molcel.2021.11.016","volume":"82","author":"SK Das","year":"2022","unstructured":"Das, S. K. et al. MYC assembles and stimulates topoisomerases 1 and 2 in a \u201ctopoisome. Mol. Cell 82, 140 (2022).","journal-title":"Mol. Cell"},{"key":"9801_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0128-8","volume":"50","author":"L He","year":"2018","unstructured":"He, L. et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp. Mol. Med. 50, 101 (2018).","journal-title":"Exp. Mol. Med."},{"key":"9801_CR53","doi-asserted-by":"publisher","first-page":"117245","DOI":"10.1016\/j.ejmech.2025.117245","volume":"285","author":"F Moraca","year":"2025","unstructured":"Moraca, F. et al. Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer. Eur. J. Med. Chem. 285, 117245 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"9801_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41588-023-01602-9","volume":"56","author":"K GCC","year":"2024","unstructured":"GCC, K. et al. The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells. Nat. Genet. 56, 23\u201326 (2024).","journal-title":"Nat. Genet."},{"key":"9801_CR55","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1158\/0008-5472.CAN-09-1304","volume":"69","author":"D Drygin","year":"2009","unstructured":"Drygin, D. et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 69, 7653\u20137661 (2009).","journal-title":"Cancer Res."},{"key":"9801_CR56","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/sj.bjc.6690480","volume":"80","author":"D Xu","year":"1999","unstructured":"Xu, D., Gruber, A., Bj\u00f6rkholm, M., Peterson, C. & Pisa, P. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br. J. Cancer 80, 1156\u20131161 (1999).","journal-title":"Br. J. Cancer"},{"key":"9801_CR57","doi-asserted-by":"publisher","first-page":"18865","DOI":"10.1074\/jbc.M114.635375","volume":"290","author":"Y Huang","year":"2015","unstructured":"Huang, Y. et al. Polo-like kinase 1 (Plk1) up-regulates telomerase activity by affecting human telomerase reverse transcriptase (hTERT) stability. J. Biol. Chem. 290, 18865\u201318873 (2015).","journal-title":"J. Biol. Chem."},{"key":"9801_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/clinchem\/47.3.519","volume":"47","author":"M Hou","year":"2001","unstructured":"Hou, M., Xu, D., Bj\u00f6rkholm, M. & Gruber, A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin. Chem. 47, 519\u2013524 (2001).","journal-title":"Clin. Chem."},{"key":"9801_CR59","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"9801_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00197809","volume":"6","author":"F Delaglio","year":"1995","unstructured":"Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277\u2013293 (1995).","journal-title":"J. Biomol. NMR"},{"key":"9801_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF00404272","volume":"4","author":"BA Johnson","year":"1994","unstructured":"Johnson, B. A. & Blevins, R. A. NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 4, 603\u2013614 (1994).","journal-title":"J. Biomol. NMR"},{"key":"9801_CR62","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1107\/S0907444998003254","volume":"54","author":"AT Br","year":"1998","unstructured":"Br, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. Sect. D. Biol. Crystallogr. 54, 905\u2013921 (1998).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"9801_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bioinformatics\/btl589","volume":"23","author":"W Rieping","year":"2007","unstructured":"Rieping, W. et al. ARIA2: Automated NOE assignment and data integration in NMR structure calculation. Bioinformatics 23, 381\u2013382 (2007).","journal-title":"Bioinformatics"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09801-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:05:48Z","timestamp":1776816348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09801-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9801"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09801-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"552"}}